Robin G Bombardi Selected Research

maftivimab

1/2021

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robin G Bombardi Research Topics

Disease

7	Infections 01/2022 - 12/2016
2	Zika Virus Infection 10/2020 - 09/2020
1	Reinfection 01/2022
1	Ebola Hemorrhagic Fever 01/2021
1	Virus Diseases (Viral Diseases) 11/2020
1	Flavivirus Infections 10/2020
1	Neoplasms (Cancer) 09/2020
1	Immunoglobulin Light-chain Amyloidosis 01/2020
1	Human Influenza (Influenza) 12/2019
1	Fetal Diseases (Embryopathy) 12/2016

Drug/Important Bio-Agent (IBA)

5	Monoclonal AntibodiesIBA 01/2021 - 12/2016
3	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2020
3	VaccinesIBA 01/2022 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2020
2	AntibodiesIBA 10/2020 - 12/2016
1	Biological ProductsIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	ansuvimabIBA 01/2021
1	atoltivimabIBA 01/2021
1	maftivimabIBA 01/2021
1	odesivimabIBA 01/2021
1	Ebola VaccinesIBA 01/2021
1	Immunoglobulin G (IgG)IBA 11/2020
1	Messenger RNA (mRNA)IBA 11/2020
1	EpitopesIBA 10/2020
1	RNA (Ribonucleic Acid)IBA 09/2020
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	Neuraminidase (Sialidase)IBA 12/2019
1	IronIBA 01/2019
1	Heme (Haem)IBA 01/2019

Therapy/Procedure

3	Therapeutics 01/2022 - 09/2020